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Peripheral  nerve  injury  can  cause  low-grade  neuroinﬂammation.
Low-grade  neuroinﬂammation  causes  imbalance  in  the  neuron–glia  interaction.
The  disturbed  neuron–glia  interaction  produces  prolonged  and exaggerated  pain  transmission.
By  targeting  glial  dysfunction  instead  of  neurons,  a new  arena  for  the development  of pharmacological  agents  is  opened.
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Background:  Acute  pain  in response  to injury  is  an important  mechanism  that  serves  to  protect  living
beings  from  harm.  However,  persistent  pain  remaining  long  after  the  injury  has  healed  serves  no  useful
purpose  and  is  a  disabling  condition.  Persistent  postsurgical  pain,  which  is pain  that lasts  more  than  3
months  after  surgery,  affects  10–50%  of patients  undergoing  elective  surgery.  Many  of these  patients  are
affected  by  neuropathic  pain  which  is  characterised  as  a pain  caused  by lesion  or disease  in the  somatosen-
sory  nervous  system.  When  established,  this  type of  pain  is difﬁcult  to treat  and  new  approaches  for
prevention  and  treatment  are  needed.
A possible  contributing  mechanism  for  the  transition  from  acute  physiological  pain  to  persistent  pain
involves  low-grade  inﬂammation  in the  central  nervous  system  (CNS),  glial  dysfunction  and  subsequently
an  imbalance  in  the  neuron–glial  interaction  that causes  enhanced  and  prolonged  pain  transmission.
Aim:  This topical  review  aims  to  highlight  the  contribution  that inﬂammatory  activated  glial  cell  dys-
function  may  have  for the  development  of persistent  pain.
Method:  Relevant  literature  was  searched  for in PubMed.
Results:  Immediately  after  an  injury  to a nerve  ending  in  the  periphery  such  as  in surgery,  the  inﬂamma-
tory  cascade  is activated  and  immunocompetent  cells  migrate  to the  site  of injury.  Macrophages  inﬁltrate
the  injured  nerve  and  cause  an  inﬂammatory  reaction  in the  nerve  cell.  This reaction  leads  to  microglia
activation  in  the central  nervous  system  and  the  release  of pro-inﬂammatory  cytokines  that  activate  and
alter  astrocyte  function.  Once  the astrocytes  and  microglia  have  become  activated,  they  participate  in
the development,  spread,  and  potentiation  of low-grade  neuroinﬂammation.  The  inﬂammatory  activated
glial  cells  exhibit  cellular  changes,  and their  communication  to each  other  and  to  neurons  is  altered.  This
renders  neurons  more  excitable  and  pain  transmission  is enhanced  and  prolonged.Astrocyte  dysfunction  can  be experimentally  restored  using  the combined  actions  of a -opioid  recep-
tor  agonist,  a  -opioid  receptor  antagonist,  and  an  anti-epileptic  agent.  To  ﬁnd  these  agents  we  searched
the  literature  for substances  with  possible  anti-inﬂammatory  properties  that  are  usually  used  for  other
purposes  in  medicine.  Inﬂammatory  induced  glial  cell  dysfunction  is  restorable  in  vitro  by a combination
of  endomorphine-1,  ultralow  doses  of  naloxone  and  levetiracetam.  Restoring  inﬂammatory-activated
glial  cells,  thereby  restoring  astrocyte–neuron  interaction  has  the  potential  to affect  pain  transmission
in  neurons.
DOI of refers to article: http://dx.doi.org/10.1016/j.sjpain.2015.10.001.
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Conclusion:  Surgery  causes  inﬂammation  at the site of injury.  Peripheral  nerve injury can  cause  low-
grade  inﬂammation  in the  CNS  known  as neuroinﬂammation.  Low-grade  neuroinﬂammation  can  cause
an  imbalance  in  the  glial–neuron  interaction  and  communication.  This  renders  neurons  more  excitable
and pain  transmission  is enhanced  and  prolonged.  Astrocytic  dysfunction  can  be  restored  in vitro by a
combination  of endomorphin-1,  ultralow  doses  of  naloxone  and  levetiracetam.  This  restoration  is  essen-
tial  for  the  interaction  between  astrocytes  and  neurons  and  hence  also  for modulation  of  synaptic  pain
transmission.
Implications:  Larger  studies  in clinical  settings  are  needed  before  these  ﬁndings  can  be  applied  in  a  clinical
context.  Potentially,  by targeting  inﬂammatory  activated  glial  cells  and  not  only  neurons,  a new  arena  for
development  of  pharmacological  agents  for  persistent  pain  is  opened.
C
1
a
t
t
h
f
a
v
s
p
u
r
r
m
r
c© 2015  The  Author.  Published  by Elsevier  B.V.  This  is an open  access  article  under the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ontents
1. Introduction:  the  clinical  problem  of persistent  pain  after  surgery  . . . . .  . .  .  . . . . . . . . .  . . .  . .  . . . . . . .  . . .  .  . . . . . .  .  .  . . . . .  .  . . . .  .  .  .  .  . . .  .  . . . .  . . . . . .  . . . .  .  .  .  . . .  .  .  .  .  75
1.1.  Neuropathic  pain  conditions  in  persistent  postsurgical  pain  (PPP)  . . .  . . . . . . .  . .  . . .  . .  .  . . . . . .  .  .  . . .  .  .  . .  .  . . . . . . .  . . . . .  .  . . . .  .  .  .  .  . .  .  . . . . . .  . . .  .  . . .  . .  .  .  .  75
1.2.  Objectives  of  this  review  . . . .  . . .  . . . .  . . .  .  .  . .  .  .  . .  . .  . .  .  . .  .  . . .  . . .  .  . . . . . . .  .  . . . . . . . . .  . . .  .  .  . . .  . . . . .  . . .  . . . . . .  .  .  . . .  .  . . .  . . .  .  .  . . .  . . .  .  . . . . . . . . . . . .  .  .  .  . . . . .  .  .  .  76
2.  Methods  .  . . . . . . . . . . .  .  . . . .  . . . . . .  . . .  .  . . .  .  . . . . . .  . . . . . . . . . . .  .  . . .  .  . . .  . . .  .  . . .  . . .  .  . . . . . .  .  . .  . . . . . .  . . . . .  . .  . .  . . . . .  .  . . . . . .  .  . . . . . .  .  .  .  . .  .  . . . .  .  .  .  . . .  .  . . . . . .  . . .  .  . . .  .  .  .  . . 76
3.  Peripheral  injuries  can  cause  low-grade  neuroinﬂammation  . . . .  .  .  . . . . .  . .  .  . . . . . .  . . .  . . .  . .  .  . . . .  . . .  .  . . . .  .  . . .  . . . . . . .  . . . . .  . .  . . . . . . . . . .  . .  .  .  .  .  . . . . .  . . . . .  . . .  . . 76
3.1.  Blood–brain  barrier  made  permeable  by  cytokines  . . .  . . .  .  . . .  .  . . . . . . .  . .  . . .  . . . . .  . . .  . .  . . . . .  . . .  .  . . . .  .  . .  . . . . .  . .  . . . .  . . . .  .  .  .  . . .  .  . . .  . . .  .  . . . . . . . .  . . . . .  . 76
3.2.  Microglia  and astrocytes’  function  are  altered  by neuroinﬂammation.  . .  . . . . . . .  . . . . . . .  .  . . .  . . . . .  . . .  . . .  . . .  .  . . .  .  .  . . . .  . . . . .  .  . . . . . . . . . .  .  .  . . . . .  .  . .  . .76
4.  Microglia  and  astrocytes’  important  role in development  of  neuropathic  pain  .  . . .  . . . . .  . . . .  .  . . .  . .  . . . . .  .  . .  . . . . .  . . .  .  .  . . . .  . .  .  . . .  . . .  . .  .  . . . .  . . .  . . .  . .  .  .  . .  .  .  76
4.1.  Microglia  initiates  neuroinﬂammation  .  . . .  .  . . .  . . .  .  . . . . . .  .  . . . . . . .  .  . . .  . .  . . .  . . . .  .  . . .  . .  .  . . . .  . . .  . . . .  . . .  . . .  .  . .  . . . .  .  .  .  .  . . .  .  .  .  .  .  .  .  .  .  . . . . . . . . .  .  . .  .  .  . .  .  . . 76
4.2.  Astrocytes  can modify  neuronal  activity . . . . . . . . . . .  . . . . . . . . . .  . . .  .  . .  . . . . .  . .  . . . . . .  .  . . . . . .  .  . . . .  .  . .  . .  . .  . . . .  . . . . . . . .  .  .  . . .  .  .  . . . . .  .  . . . .  . .  .  .  .  .  .  . .  .  .  .  .  . . .76
4.2.1. Astrocytic  calcium  (Ca2+) signalling  .  . . .  .  . . . . . .  .  . . . .  .  . .  . . . . . . .  . . .  . . . . . .  .  . . .  . . . . . . . . . . .  . . . . . . .  .  . . . .  . . . . .  .  . . . .  .  .  . . .  .  . . . . . . . . . . . . .  . . .  . . .  . . 76
4.2.2. Gap  junction  coupling  . .  . . . .  .  . . .  .  . . . . . . .  . . .  . . .  . . .  . . . .  . . . .  . .  . . . . .  . .  . . . .  .  .  .  . . . . . .  .  . . . .  . . . .  .  . . .  . . .  . . . . . . . .  .  .  . . . . .  . . . . . .  .  . .  .  . .  . . .  .  . . .  . . . . . . 77
4.2.3.  Glutamate–glutamine  cycle  .  . . .  . . . .  . . . .  .  . . . . . .  .  . . . .  . . . . . . .  . .  .  . . .  . . . . .  . .  .  . .  . . . .  .  . . .  . . . . . . . .  . . . . . . .  . . . . .  . . .  .  .  .  . . .  .  . . . . .  .  . . .  . .  .  . . .  . . .  .  . . . 77
5. Astrocytic  cellular  dysfunction  in inﬂammatory  conditions  . .  .  . . .  .  . . . .  . .  . . . . .  . .  .  . . .  .  . . . . .  . . .  .  . . . .  .  . . .  . . . .  .  . . . . . . .  . .  . . . .  . . . .  . . .  .  . . . . . . . . . .  . .  . .  .  .  .  . .  .  . . . 77
5.1.  Toll like  receptor-4  is  a pro-inﬂammatory  receptor  . . . .  . .  .  .  . . . . . . . . . . . . .  . .  . . .  . .  . .  . . .  . .  . . .  . . .  . . . . . . .  . . .  . . .  .  . . . .  .  . . . .  . . . . .  .  . . .  . .  .  . .  . . . . . . .  . . . .  .  . .  77
5.2.  Astrocytes  communicate  with  Ca2+ waves.  . . . . . . .  . . .  .  . . .  . . . .  . . . .  . . . . . . .  . .  . . .  . . . . . . .  . . .  .  . . . . .  . .  .  . . . . .  .  . . . .  . .  .  .  . . .  .  . . . .  .  . .  .  . .  .  . . . . . .  . .  .  .  . .  .  .  .  .  .  . .77
5.3.  Na+/K+ ATPase  modulates  Ca2+ signalling.  .  . . . .  . . .  .  . . . . . .  .  . . . .  .  . . .  .  . . .  . . . . .  . . . . .  . . .  . . . . . .  . . . . .  . .  .  .  . . .  . . .  . .  . . .  . .  .  .  . .  .  . . . . . . . . . . .  . .  .  . .  .  . . .  . . . . .  . . .77
5.4. An intact  cytoskeleton  is needed  for  Ca2+ signalling  . . .  .  .  . . . . . .  .  . .  . . . .  . . . .  .  . . . . .  .  .  . . . . . .  .  . . . .  . .  .  . . . . .  .  . . . . . . . .  . . . .  .  . .  . . . . . .  .  .  .  .  . .  . . . . . . .  . . .  .  .  . .  78
5.5.  Pro-inﬂammatory  cytokine  IL-1  closes  gap  junctions  . .  .  . . . . .  . . .  .  . .  . .  .  . . . . . . .  . . . . . . .  .  . .  . . . . .  . . .  . . . . .  . . .  . . . . .  . . . . . . .  . . . . . .  . .  .  .  . .  . . .  . . . . . . . . . . . 78
5.6.  Inﬂammation  disrupts  astrocytes’  communication  . . .  .  . . . .  . . .  .  . . . . . .  . . . . . .  . .  .  . . .  .  . . .  .  . . . . . . .  . .  .  . . .  .  . . .  . . . .  .  . . . .  . . . . .  .  .  . .  .  .  .  . . .  .  . . . . .  .  . .  .  .  . .  .  . .  78
6.  Reversing  glial  dysfunction  (Fig.  3) .  .  . . .  .  . . . . . . . . . . . . . . .  . . .  . . .  . . . . . . . .  .  . .  . . .  . . .  . . . . . .  .  . . . . . . .  .  . . .  . . . .  . . .  . . . . .  . .  .  . .  . . .  . .  . . .  .  .  . . .  .  .  .  . . .  .  . . . . . .  . . .  .  .  . .  . .  .  .  .  78
6.1.  Endomorphin-1  stimulates  the  -opioid  receptor  and  Na+/K+ATPase  .  .  .  . . .  . . .  . . . . . .  .  . . .  .  . . . .  .  . . . . . . .  . . . . . .  .  .  . . . . . . .  .  .  . .  . . . . . .  . . . . .  .  .  .  . .  .  .  .  . . . 78
6.2. Naloxone  inhibits  the  excitatory  second  messenger  protein  Gs and  restores  actin  ﬁlaments  .  . . . . . . .  . .  .  . . . . .  . . .  .  . . . . . . . . . . .  . .  .  . . .  . .  .  .  .  . .  . . .  . .  78
6.3.  Levetiracetam  opens  blocked  gap  junctions  . .  .  .  . . .  . . . . . . .  .  . . . .  . . .  .  . . . . .  .  . . . . . .  .  . . . . . . .  . . . .  .  . .  .  . . .  .  . . .  . .  .  . . . . . . .  . . . .  .  . . . .  .  .  . .  . .  .  . . . . .  . . . .  .  . . .  . . .  78
6.4.  Experimental  studies  of  the combination  endomorphin-1,  naloxone  and  levetiracetam  . . . . .  . . . . . . .  .  . .  . . . . .  .  . . . . .  . .  .  . .  .  . . . . . .  . .  .  . .  .  . . . .  .  . .  . . 79
7.  Clinical  applications  . . .  . . . .  . . .  .  . . .  .  . .  .  .  . .  .  .  . . . . . . . . . . . . . .  . . . .  .  . . . . . .  . . . . . . .  .  . .  . . . . .  .  . . . .  . . .  . . . . .  . .  . . . . .  . . .  . .  . . . . . .  . . . . . . .  .  . .  . . .  .  . . . . . .  . . . . . .  .  .  .  . . . . .  . .  . . 79
8.  Conclusions  . . . .  . .  .  . .  .  . . .  .  . . .  .  . . . .  . . . . . .  . . . .  . . .  .  .  . .  .  .  . .  .  . . .  .  . . . . . .  .  . . . . . . . . . . .  . . .  . .  . . . . .  . .  . . .  . . .  .  .  . . .  . . . . .  . .  . . .  .  . .  .  . . . .  .  . . . .  . . . . .  .  .  . .  .  .  .  . . .  .  . . . . .  . . . . . . . .  79
9.  Implications  . .  . .  .  . .  . . .  . . . .  . . . . . . .  . . . .  . . . .  .  . .  .  .  . . . . . . . . . .  . . . . . . .  .  . . . . . . . . .  . . . . . .  . . . .  . . .  . . . . . . .  . . . . . . .  .  . . .  . . . . .  . . .  . . .  . . . .  . . . . .  .  . .  . .  .  . . . . . . .  .  .  .  . .  .  .  .  .  . . .  .  . . . 79
Conﬂicts  of  interest  .  . . .  .  . . .  .  . .  . . . .  . . .  .  . . .  .  . .  .  .  . . .  . . .  . . . .  . . . .  . . . . . .  . . . .  . . . . . .  . . . . . . .  . . . .  . .  . . . . . . .  .  . . .  .  . . . .  .  . . . . . . .  . . . . . . .  . .  .  . . .  . . . . . .  .  .  .  .  . .  .  . .  . .  .  . .  . . . . . .  80
Acknowledgements .  . . . . . .  . . . .  . . .  .  . . .  . . .  . . . .  . . .  .  . . .  .  . . .  .  . . .  . . .  .  . . .  .  . .  .  .  . . .  . .  .  . . . . .  .  . . . . . . . . . .  .  .  . . . . .  .  .  . . .  . . . . . . . .  .  . . . . . . . . . .  .  .  . . . . .  . .  .  .  .  .  . . .  .  . . . . .  . . . .  . .80
References  .  .  . . . . . .  . . .  . . . .  . . . .  . . .  .  . . .  .  . . .  .  . . .  . . . . . . . . . . . .  . . .  . . .  . . . . .  . . . . . . .  .  . . . . .  .  . .  .  . . . .  . . .  . . .  . . .  . . . .  . . .  . . . . . . .  .  . . . . . .  .  .  . . . . .  . .  .  . .  . . . . . . . . .  .  . . .  .  . .  .  .  .  .  .  . 80
. Introduction: the clinical problem of persistent pain
fter surgery
Acute pain in response to injury is an important mechanism
hat serves to protect living beings from harm. The pain signals
ransmitted from the site of injury to the brain cause us to avoid
armful, noxious stimuli. However, severe pain that is sustained
or a long time after the injury has healed serves no useful purpose
nd is a disabling condition. Persistent pain is devastating for indi-
iduals and causes substantial health impairment and signiﬁcant
ocial, ﬁnancial, and work-related difﬁculties [1–3]. From a social
oint of view, persistent pain is a large burden and results in the
se of extensive resources for sick leave, disability retirement, and
ehabilitation.
Persistent postsurgical pain, which is often deﬁned as pain that
included 2043 patients [9] demonstrated that 12% of patients who
underwent an elective, mixed type of surgery developed moderate
persistent postsurgical pain and 7% developed severe persistent
postsurgical pain. Persistent postsurgical pain after a number of
surgical procedures has been described, the prevalence of persis-
tent postsurgical pain varies with the type of surgery, ranging from
50% for limb amputation, 30% for breast surgery, and 10% for hernia
repair [5,10,11].
1.1. Neuropathic pain conditions in persistent postsurgical pain
(PPP)
Persistent postsurgical pain is strongly associated with neuro-
pathic pain [12,13]. Depending on the type of surgery, neuropathicemains for 3 months or more after surgery, is the second most com-
on  cause of chronic pain after degenerative disease [4]. Recent
eports regarding persistent postsurgical pain conﬁrm that it is a
omplex and highly signiﬁcant clinical problem [5–8]. A study thatpain is experienced by 3% (laparoscopic surgery) to 68% (breast
surgery) of patients with persistent postsurgical pain. Neuropathic
pain is characterised by lesion to or disease of the somatosensory
nervous system [14,15]. It is recognised by pain that is distributed
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nd localised along the innervation territory of the affected nerve,
nd it is always accompanied by a sensory disturbance, such as
yperesthesia or hypoesthesia, in the affected area. When estab-
ished, neuropathic pain is difﬁcult to treat, and conventional pain
herapy is often insufﬁcient.
It seems that nerve damage is a prerequisite for the develop-
ent of neuropathic pain. However, nerve damage does not always
roduce neuropathic pain [13,16].
Possible mechanisms for the transition from acute physiological
ain to persistent pain that remains after an acute injury has healed
nclude nerve injury followed by inﬂammation in the peripheral
ervous system (PNS) and CNS [17,18].
.2. Objectives of this review
This review will focus on neuroinﬂammation and subsequent
lial dysfunction [19] as possible contributors to the development
f persistent postsurgical neuropathic pain [20–22]. Other possi-
le mechanisms for persistent pain include long-term potentiation,
eripheral as well as central sensitisation, neuronal plasticity, neu-
al ectopic activity and disinhibition [23–25]. These entities, which
ll concur with our theory, are not the main focus of this review
nd therefore, will not be further discussed here.
. Methods
Concerning the literature search for this paper a convenient
election of publications from searching PubMed was used. Search
ords were pain, neuroinﬂammation, glia, astrocytes, microglia,
ersistent postsurgical pain, persistent postoperative pain, neu-
opathic pain, inﬂammation, morphine, endomorphin, naloxone,
evetiracetam and also different combinations of these.
. Peripheral injuries can cause low-grade
euroinﬂammation
When an injury occurs in peripheral tissue, pro-inﬂammatory
ediators, such as nitric oxide, bradykinin, tissue factors, and
rostaglandins, are released into the bloodstream, and white blood
ells are attracted to the injury site. The endothelium that lines
he blood vessels becomes permeable, and leucocytes migrate from
he blood vessels to the injury site [26]. A peripheral inﬂammatory
rocess can also induce low-grade inﬂammation in the CNS; this
rocess is known as neuroinﬂammation [27,28].
.1. Blood–brain barrier made permeable by cytokines
After a peripheral nerve injury, inﬂammatory activated leu-
ocytes release pro-inﬂammatory cytokines [29]. These cytokines
ause the blood–brain barrier (BBB) to become permeable, thereby
llowing leucocytes to migrate through and transform into
icroglia in the CNS [30–33]. The activated microglia produce more
ro-inﬂammatory cytokines, such as IL-1 and TNF-. In turn, IL-
 activates astrocytes, which also release the pro-inﬂammatory
ytokine IL-1. This combined response causes a change in the
strocyte network signalling, thus potentiating neuronal pain
ransmission [34–37]. Furthermore, this reaction is associated with
he development of new synapses and dysfunction of existing
ynapses [38–43].
Neuroinﬂammation can also be initiated when a local peripheral
njury produces inﬂammatory activation in the CNS [44], which is
onveyed by neurogenic sites of action. Macrophages inﬁltrate the
njured nerve [45] and cause an inﬂammatory reaction in the nerve
ells.of Pain 10 (2016) 74–81
3.2. Microglia and astrocytes’ function are altered by
neuroinﬂammation
This reaction leads to microglia activation in the CNS and the
release of pro-inﬂammatory cytokines that activate and alter astro-
cyte function [46,47].
Microglia and astrocytes are non-excitable neural cells that play
an active role in the development of neuroinﬂammation [48–51].
In the last few years, it has become clear that glial cells have
important metabolic and immune functions [52] and may  play
an important role in the modulation of synaptic pain transmis-
sion [53,54]. Astrocytes and microglia are glial cells that surround,
support, and interact with neurons in the CNS. They respond to
inﬂammatory stimuli and may  play an important role in mod-
ulating the inﬂammatory activity in the CNS, as observed after
peripheral injuries [55]. Astrocytes are coupled in networks and
communicate with each other and with neurons [56,57] thereby
modulating neuronal activity [58]. Inﬂammation causes dysfunc-
tion in glial–neuron communication due to inﬂammatory-induced
alterations in astrocyte function that disturb the two-way interac-
tion between astrocytes and neurons. This disturbance results in
increased excitability in neurons, and synaptic pain transmission is
enhanced and prolonged [59,60].
4. Microglia and astrocytes’ important role in development
of neuropathic pain
The CNS consists of neurons and glial cells; the latter account
for 70% of the cells. Microglia and astrocytes are important for the
development of persistent pain [61]. Additionally, dorsal root gan-
glion satellite cells, which are astrocyte-like cells in the PNS, may
play a role in the development of neuropathic pain [53]. However,
they will not be discussed further in this review.
4.1. Microglia initiates neuroinﬂammation
Microglia are resident macrophages in the CNS, and they rapidly
respond to an injury by proliferating, changing shape and produc-
ing pro-inﬂammatory cytokines [25]. Within 2 days of a peripheral
nerve injury, there is marked proliferation of microglia in the spinal
cord [62]. Hence, microglia are most likely the cell type that initi-
ates inﬂammation in the CNS, thereby leading to further activation
and spread of inﬂammation by the astrocytes [46].
4.2. Astrocytes can modify neuronal activity
Astrocytes are the most abundant cells in the CNS. They are star-
shaped cells with long, slender processes. Astrocytes are coupled
by gap junctions in syncytial networks and occupy a strategic posi-
tion between the vasculature and the neurons, where they monitor
and modify neuronal activity and transmitter release [59]. Astro-
cytes can release a rich variety of neuroactive substances, and they
also express receptors for these substances. They surround neural
synapses with their end-feet and monitor and modulate synaptic
activity. One astrocyte can contact approximately 100,000 synapses
[63,64], which makes their impact on synaptic transmission signif-
icant.
4.2.1. Astrocytic calcium (Ca2+) signalling
Astrocytes display a form of excitability that manifests as an
increased intracellular Ca2+ concentration. Stimuli, such as trans-
mitters released from neurons and glial cells, can evoke Ca2+
elevation in single astrocytes, which passes to adjacent astrocytes
and leads to a Ca2+ wave that can propagate over long distances
[65–67].
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Fig. 2. In an inﬂammatory state, (1) TLR4 is upregulated; (2) Ca2+ waves oscillate;
(3)  Na+/K+-ATPase is downregulated; (4) actin ﬁlaments are disrupted; and (5) IL-
1  release is increased, and gap junctions close. Furthermore, there is an increasedig. 1. In the normal state, (1) TLR4 is downregulated; (2) Ca2+ waves are controlled;
3)  Na+/K+-ATPase works optimally; (4) the actin ﬁlaments are well-organised; and
5)  the IL-1 release is minimal and gap junctions are open [90].
.2.2. Gap junction coupling
For this machinery to function, intercellular channels that are
eferred to as gap junctions appear to be necessary [68]. These
hannels enable direct exchange of ions, metabolites, and small
olecules (less than 1.5 kDa in size) between contiguous cells [69].
onnexin 43 (Cx43) is the primary gap junction protein [70]. Astro-
ytes in most parts of the CNS use two types of Ca2+ communication:
ntercellular communication through gap junctions and extracel-
ular communication through diffusion of adenosine triphosphate
ATP), which then binds to purinoceptors on adjacent cells [70].
.2.3. Glutamate–glutamine cycle
One of the roles of astrocytes is to clear the synaptic cleft of
lutamate released from the neurons, thereby preventing neuro-
oxicity due to excessive amounts of glutamate [71,72]. Neuronal
ctivity releases glutamate into the neural synapse. The glutamate
s taken up by astrocytes and converted to glutamine by the enzyme
lutamine synthetase. Glutamine is released back into the synaptic
left, taken up by neurons, and metabolised to glutamate, which is
gain released into the synaptic cleft; this process is referred to as
he glutamate–glutamine cycle [73,74].
The inﬂammatory activated astrocytes cannot sufﬁciently clear
he synaptic cleft of glutamate. Glutamate is an excitatory neuro-
ransmitter, and the increased glutamate level in the synaptic cleft
akes the neurons more excitable [75].
. Astrocytic cellular dysfunction in inﬂammatory
onditions
Cellular changes that occur during neuroinﬂammation render
he astrocyte networks unable to interact appropriately with neu-
ons, thereby altering synaptic transmission (Figs. 1 and 2). During
nﬂammation, the expression and afﬁnities of several receptors are
hanged.extracellular release of ATP, which causes Ca2+ release in adjacent astrocytes via the
P2X7 receptor [90].
5.1. Toll like receptor-4 is a pro-inﬂammatory receptor
In astrocytes, Toll-like receptor 4 (TLR4) is an inﬂammatory
receptor that responds to lipopolysaccharide (LPS) by increasing
its expression and activity [76,77]. Activation of TLR4 leads to an
increase in the release of the pro-inﬂammatory cytokines TNF-
and IL-1 [78]. Activation of TLR4 can be inhibited by ultralow doses
of naloxone [79] and interestingly, it can be increased by prolonged
morphine administration [80].
5.2. Astrocytes communicate with Ca2+ waves
Astrocytes communicate and modulate synaptic activity
through Ca2+ waves. Release of Ca2+ can be stimulated by
substances released from both neurons and glial cells [81,82].
Receptors on the surface of astrocytes are coupled to G proteins
and release Ca2+ from the endoplasmic reticulum via phospholi-
pase C and inositol-triphosphate (IP3) [83]. These Ca2+ waves can
propagate from one cell to another via gap junctions. An increase
in cytosolic Ca2+ leads to release of gliotransmitters, i.e., substances
that can inﬂuence and modulate synaptic transmission [68]. Pro-
longed neuroinﬂammation causes dysfunction of this signalling
system [84,85].
5.3. Na+/K+ ATPase modulates Ca2+ signalling
Inﬂux of Ca2+ across the plasma membrane is driven by the
Na+ electrochemical gradient across the plasma membrane and
the Na+ pump, Na+/K+-ATPase, which indirectly modulates Ca2+signalling [86]. Inﬂammatory stimuli disturb the Ca2+ homeosta-
sis in astrocyte networks, possibly by interfering with the activity
of Na+/K+-ATPase [86].
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Fig. 3. Treatment with a combination of endomorphin-1, naloxone and levetirac-
etam restores (1) TLR4 expression, (2) Ca2+ release, (3) Na+/K+-ATPase expression,
(4) actin ﬁlament organisation, and (5) release of IL-1. Furthermore, the combi-
nation unblocks gap junctions and promotes propagation of the intercellular Ca2+
waves through the gap junctions [90].
In our experimental work, levetiracetam was  used for its anti-
inﬂammatory properties. Levetiracetam has been shown, in8 L. Block / Scandinavian Jo
.4. An intact cytoskeleton is needed for Ca2+ signalling
Na+/K+-ATPase, the actin ﬁlaments that constitute the
ytoskeleton, and the endoplasmic reticulum are associated
hrough the adaptor protein ankyrin B [87]. Na+/K+-ATPase is
onnected to the actin ﬁlaments by the protein ankyrin B, and
he actin ﬁlaments are connected to the endoplasmic reticulum
y the same protein. If the actin ﬁlaments are disrupted, the
a2+ release is disturbed. An intact cytoskeleton is required for
ropagation of Ca2+ waves in astrocytes, and disruption of the
ytoskeleton abolishes Ca2+ waves by changing the balance among
he Ca2+-regulating processes [88]. In inﬂammatory states, the
ytoskeleton is disrupted.
.5. Pro-inﬂammatory cytokine IL-1  ˇ closes gap junctions
In the CNS, IL-1 is mainly produced by microglia that are active
n initiating the inﬂammatory process, whereas astrocytes, which
lso produce signiﬁcant amounts of IL-1, are dominant in main-
aining neuroinﬂammation [89]. The increase in IL-1 closes the
ap junctions, thereby inhibiting the normal propagation of Ca2+
aves through the astrocytic networks [90].
.6. Inﬂammation disrupts astrocytes’ communication
In inﬂammatory states, the increase in pro-inﬂammatory
ytokines leads to increased production of ATP. These changes
isturb the normal Ca2+ signalling [91], which can result in Ca2+
scillations. Gap junctions close because of high levels of IL-1,
nd the intercellular Ca2+ waves and propagation from cell to cell
re attenuated [92]. The increased extracellular release of ATP acts
n purinergic receptors on adjacent astrocytes, consequently stim-
lating the release of intracellular Ca2+ in adjacent cells [93]. This
timulation leads to poorly controlled extracellular propagation of
he Ca2+ waves, and the increased intracellular Ca2+ release exhibits
scillatory behaviour [70] (Fig. 2).
. Reversing glial dysfunction (Fig. 3)
The cellular changes that occur during experimental neu-
oinﬂammation render the astrocyte network unable to interact
ppropriately with neurons and synaptic transmission [94]. To
estore the cellular changes caused by the experimental neu-
oinﬂammation described above, we searched the literature for
ubstances with possible anti-inﬂammatory properties that are
sually used for other purposes in medicine.
.1. Endomorphin-1 stimulates the -opioid receptor and
a+/K+ATPase
Endomorphin-1 (EM-1) is a peptide and an endogenous -
pioid receptor agonist [95–97]. EM-1 is released from nerve
ndings into the general circulation [98]. It has also been found in
nﬂammatory tissue, implying that it may  interact with immune
ells. Astrocytes possess -opioid receptors, and endomorphins
ay  play a role in the control of neuroinﬂammatory activity
99,100]. Morphine activates the -opioid receptor, which in turn
ctivates the second messenger protein Gi/o. The complex of -
pioid receptor and Gi/o works by multiple mechanisms to inhibit
eural pain impulses, thereby decreasing pain sensations in the
rain [101,102]. EM-1 and morphine have been shown to stimulate
a+/K+-ATPase activity in vitro [103].6.2. Naloxone inhibits the excitatory second messenger protein Gs
and restores actin ﬁlaments
Naloxone is an effective -opioid receptor antagonist when
used at higher doses (mg), and it is widely used in clinical practice
to reverse opioid overdoses [104].
At ultralow doses (pg) the mechanism of naloxone is different. In
states of low-grade neuroinﬂammation, such as chronic pain states
[31,105], and even after long-term morphine treatment [106,107]
the -opioid receptor shifts its coupling from the inhibitory Gi/o
protein to the excitatory Gs protein [108,109]. This switch causes
diminished pain relief and increased morphine tolerance. Nalox-
one at ultralow concentrations has the ability to block -opioid
receptor-coupling to the excitatory Gs protein and causes the -
opioid receptor to couple to the inhibitory Gi/o protein [110,111].
Naloxone can also restore to some extent, inﬂammatory disrupted
actin ﬁlaments [77].
6.3. Levetiracetam opens blocked gap junctions
Levetiracetam is an effective anti-epileptic drug. Levetirac-
etam inhibits the neural release of transmitters into the synaptic
cleft by binding to a protein that regulates exocytosis [112,113].inﬂammation-reactive astrocyte models, to restore functional gap
junction coupling [114] by increasing the expression of connexin
43, the predominant gap junction protein, and decreasing the
enhanced IL-1 level [115].
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Fig. 5. Effects of interventions on perceived quality of sleep (percentage of subjects),ig. 4. Effects of interventions on pain (percentage of subjects) expressed as
Improved” (dark blue), “Unchanged” (medium blue), or “Worse” (light blue). NAL,
aloxone. N = 11 [90].
.4. Experimental studies of the combination endomorphin-1,
aloxone and levetiracetam
The combination of the endogenous -opioid agonist
ndomorphin-1, the -opioid antagonist naloxone at ultralow
oncentrations and the anti-epileptic drug levetiracetam yielded
romising results as regards restoration of cellular changes caused
y experimentally induced inﬂammation [94].
During inﬂammation, the -opioid receptor switches its nor-
al  activation target from the Gi/o protein to the Gs protein
110,111,116]. At ultralow doses, naloxone blocks Gs and forces Gi/o
ctivation, which promotes normal endomorphin-1-induced Ca2+
elease [117]. Second, the addition of levetiracetam in combina-
ion with endomorphin-1 and ultralow doses of naloxone restored
he actin ﬁlaments, attenuated the release of IL-1 and unblocked
he gap junctions, thus enabling restoration of Ca2+ signalling
Fig. 3). Experimentally, a combination of endomorphin-1, ultralow
oses of naloxone and levetiracetam can attenuate inﬂammatory-
nduced astrocytic changes and restore intercellular Ca2+ signalling.
t is possible that this type of action inﬂuences the intercellular
ommunication between astrocytes and exerts effects on synaptic
ain transmission in neurons. Nevertheless, there is a large dif-
erence between results produced in a laboratory using cellular
ultures and outcomes in a clinical setting. Thus, these results need
o be assessed in a clinical setting.
. Clinical applications
Our group performed a pilot study consisting of eleven patients
ith persistent pain following multiple surgeries, who were being
reated with continuous intrathecal morphine administration; in
he study, ultralow-dose naloxone was administered via the same
oute [118]. The reason for not using the above discussed triple
ombination is that we  wanted the option to investigate the effect
f each agent individually in vivo.
Two dosages of naloxone were used: 40 ng/24 h and 400 ng/24 h.
either of these interventions was associated with statistically sig-
iﬁcant changes in pain status, as assessed with the Numeric Rating
cale (NRS) (Fig. 4). Nevertheless, three study patients who  did not
mprove with placebo experienced marked pain relief with one of
he doses of adjuvant intrathecal naloxone.
An unexpected ﬁnding was that adjuvant naloxone 40 ng/24 h
igniﬁcantly improved the perceived quality of sleep compared
ith the placebo (Fig. 5) [118].
The underlying mechanisms of the clinical ﬁndings are com-
lex. In healthy states, morphine stimulates the -opioid receptor,expressed as “Improved” (dark blue), “Unchanged” (medium blue), or “Worse” (light
blue). NAL, naloxone. p indicates a comparison between placebo and NAL 40 ng/24 h.
N  = 11 [90].
which in turn stimulates the inhibitory Gi/o protein; however, in
states of low-grade inﬂammation, this coupling decreases, and
the coupling of the -opioid receptor to the excitatory Gs protein
increases [119–121]. As described above, using cellular cultures, it
has been demonstrated that ultralow doses of naloxone can inhibit
the Gs protein, and the -opioid receptor coupling to the Gi/o pro-
tein subsequently increases [122].
8. Conclusions
Peripheral nerve injury can cause low-grade inﬂammation in
the CNS known as neuroinﬂammation. Low-grade neuroinﬂamma-
tion can cause an imbalance in the glial–neuron interaction and
communication.
Experimentally induced inﬂammation causes changes in astro-
cyte function. The expression of the inﬂammatory receptor TLR4
is increased, the Ca2+ wave signalling is changed, the expression
of Na+/K+-ATPase is decreased, the actin ﬁlaments are disorga-
nised, and the release of IL-1 is increased. These changes cause
an imbalance in the astrocyte–neuron interaction that renders the
neurons overly excitable, which produces enhanced and prolonged
pain signalling.
The disturbed signalling can be restored in vitro by treating
astrocytes with a combination of endomorphin-1, and ultralow
doses of naloxone and levetiracetam. Ultralow doses of nalox-
one block the excitatory Gs protein. Subsequently, the action of
endomorphin-1 on the inhibitory Gi/o protein is enhanced. Lev-
etiracetam attenuates the inﬂammatory-induced release of glial
IL-1. The combination of endomorphin-1, naloxone, and levetirac-
etam successfully counteracts the inﬂammatory-induced cellular
changes caused by LPS. This restoration is essential for intercel-
lular astrocyte Ca2+ communication and the interaction between
astrocytes and neurons and hence also for modulation of synaptic
pain transmission.
9. Implications
Surgery or trauma causes inﬂammation at the site of injury.
Nerve injury causes low-grade inﬂammation in the CNS and
PNS. Neuroinﬂammation that persists after the acute injury has
healed may  be an important component of establishing persistent
postsurgical neuropathic pain. Restoring inﬂammatory-activated
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strocytes, thereby inhibiting enhanced pain transmission in neu-
ons, is a potentially interesting method. Larger studies in clinical
ettings are needed before the abovementioned ﬁndings can be
pplied in a clinical context. Potentially, by targeting inﬂammatory
ctivated glial cells and not only neurons, a new arena for develop-
ent of pharmacological agents for persistent pain is opened.
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